Literature DB >> 34267876

Therapeutic Modulation of NLRP3 for Treatment of Cancer, Alzheimer's Disease, and Trauma.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2021        PMID： 34267876      PMCID： PMC8274072          DOI： 10.1021/acsmedchemlett.1c00320

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  5 in total

Review 1.  Strategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space.

Authors:  Adam G Schwaid; Kerrie B Spencer
Journal:  J Med Chem       Date:  2020-12-22       Impact factor: 7.446

Review 2.  Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases.

Authors:  Xiangna Zhang; Ana Xu; Jiahui Lv; Qiuqiong Zhang; Yingying Ran; Chao Wei; Jingde Wu
Journal:  Eur J Med Chem       Date:  2019-10-30       Impact factor: 6.514

3.  An overview of disease models for NLRP3 inflammasome over-activation.

Authors:  Hongliang Zhang; Ayesha Zahid; Hazrat Ismail; Yujie Tang; Tengchuan Jin; Jinhui Tao
Journal:  Expert Opin Drug Discov       Date:  2020-12-21       Impact factor: 6.098

4.  Recent Progress on the Discovery of NLRP3 Inhibitors and their Therapeutic Potential.

Authors:  Ma Su; Weiwei Wang; Feng Liu; Huanqiu Li
Journal:  Curr Med Chem       Date:  2021       Impact factor: 4.530

Review 5.  The NLRP3 inflammasome: an emerging therapeutic target for chronic pain.

Authors:  Ruixiang Chen; Chengyu Yin; Jianqiao Fang; Boyi Liu
Journal:  J Neuroinflammation       Date:  2021-03-30       Impact factor: 8.322
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.